14/10/2024
Voluntary Announcement – Potential Acceptance Notice of Investigational New Drug Application of Recombinant Anfibatide Injection
01/08/2024
Voluntary Announcement – The First Patient in Hong Kong Receives AU409, a Novel Drug Product Manufactured by Zhaoke Guangzhou, in a Phase I Liver Cancer Clinical Trial
28/11/2023
Voluntary Announcement – Adasuve Obtains Drug Registration Certificate
21/08/2023
Voluntary Announcement – Update on an Investigational Anesthesia Product
21/08/2023
Voluntary Announcement – Apremilast Tablet Obtains Drug Registration Certificate
09/06/2023
Voluntary Announcement – INOmax DSIR Plus Delivery System Obtains Medical Device Registration Certificate
16/02/2023
Voluntary Announcement – Business Update on the Extended Phase 2b Study of Tafoxiparin by Dilafor
19/01/2023
Voluntary Announcement – Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List
09/11/2022
Voluntary Announcement – Approval of a Drug Product Manufactured by Zhaoke Guangzhou to Conduct Clinical Trial in the United States
26/10/2022
Voluntary Announcement – Completion of Patient Enrolment for a Phase III Clinical Trial of Intrarosa
29/09/2022
Voluntary Announcement – Obtaining Drug Marketing Authorisation of Azilsartan Tablets
23/08/2022
Voluntary Announcement – Obtains Global License of SURFAXIN, SURFAXIN LS and AEROSURF from Windtree Therapeutics, Inc.
21/06/2022
Voluntary Announcement – Teglutik Obtains Drug Registration Certificate
19/05/2022
Voluntary Announcement – Natulan Obtains Drug Registration Certificate
13/05/2022
Voluntary Announcement – Update on an Investigational Oncology Drug Product
21/04/2022
Voluntary Announcement – INOmax obtains Drug Registration Certificate
16/11/2021
Voluntary Announcement – Update on an Investigational Oncology Drug Product
27/10/2021
Voluntary Announcement – Business Update on the In-Licensing and Research and Development of Tafoxiparin of the Group
27/10/2021
Voluntary Announcement – New Drug Application of Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer Submitted and Accepted by NMPA
04/10/2021
Voluntary Announcement – Update on the Commercialisation and Research and Development of Cetraxal Plus of the Group
27/09/2021
Voluntary Announcement – Update on the Research and Development of an Investigational Oncology Product
13/09/2021
Voluntary Announcement – Update on an Investigational Gynecology Drug Product
01/09/2021
Voluntary Announcement – Appointment of Chief Medical Officer
05/08/2021
Voluntary Announcement – Business Update on an Investigational Continuous Glucose Monitoring System of an Associated Company of the Group
22/07/2021
Voluntary Announcement – Update on an Investigational Oncology Drug Product
21/06/2021
Voluntary Announcement – Business Update on the Licensed-in of Bredinin from Asahi Kasei Pharma Corporation
07/06/2021
Voluntary Announcement – Official Release of the Result of Phase I Clinical Trial on the Safety and Antithrombotic Efficacy of Anfibatide
02/06/2021
Voluntary Announcement – Business Update on the In-licensing and Research and Development of Tafoxiparin of the Group
21/05/2021
Voluntary Announcement – Sodium Phenylbutyrate Granules Obtained Approval for Drug Registration
12/04/2021
Voluntary Announcement – Update on Research and Development of an Investigational Ophthalmology Product of an Associated Company of the Group
11/03/2021
Voluntary Announcement – Update on an Investigational Direct Oral Anticoagulant
11/03/2021
Voluntary Announcement – Update on an Investigational Ophthalmology Product of an Associated Company of the Group
05/03/2021
Voluntary Announcement – Socazolimab Obtained Approval for a Phase III Clinical Trial from NMPA
04/03/2021
Voluntary Announcement – Update of Business Development with KPC Pharmaceuticals, Inc.
09/02/2021
Voluntary Announcement – Update on the Research and Development of an Investigational Oncology Product
09/02/2021
Voluntary Announcement – Update on an Investigational Dermatology Product
05/02/2021
Voluntary Announcement – Fondaparinux Sodium Injection Obtained Approval for Drug Registration
05/02/2021
Voluntary Announcement – Update on an Investigational Oncology Product
02/02/2021
Voluntary Announcement – Memorandum of Understanding of an Associated Company in relation to the Strategic Partnership with Singapore Eye Research Institute
15/01/2021
Voluntary Announcement – Update on an Investigational Gynecology Drug Product
13/01/2021
Voluntary Announcement – Update on an Investigational Ear Drug Product
29/12/2020
Voluntary Announcement – Update on Research and Development of an Investigational Ophthalmology Product of an Associated Company of the Group
11/12/2020
Voluntary Announcement – Trazodone Hydrochloride Tablet Obtained Drug Registration Certificate from China’s National Medical Products Administration
30/11/2020
Voluntary Announcement – Update on Research and Development of an Investigational Ophthalmology Product of an Associated Company of the Group
20/11/2020
Voluntary Announcement – Update on the Possible Spin-Off and Separate Listing of Zhaoke Ophthalmology Limited
17/11/2020
Voluntary Announcement – Completion of Series B Shares Subscription in an Associated Company
16/11/2020
Voluntary Announcement – Business Update on the In-Licensing and Research and Development of Ophthalmology Products of an Associated Company of the Group
06/11/2020
Voluntary Announcement – Update on an Investigational Anaesthesia Product
23/10/2020
Voluntary Announcement – Establishment of the Group Commercial Operations Centre
20/10/2020
Voluntary Announcement – Business Update on the In-Licensing and Research and Development of Ophthalmology Products of an Associated Company of the Group
11/10/2020
Voluntary Announcement – Reduction in Equity Interest in an Associated Company
03/09/2020
Voluntary Announcement – Update on an Investigational Inhaled Antipsychotic Product
03/09/2020
Voluntary Announcement – Update on the Possible Spin-off and Separate Listing of China Ophthalmology Focus Limited
31/08/2020
Voluntary Announcement – Update on an Investigational Anaesthesia Product
21/08/2020
Voluntary Announcement – Update on the Introduction and Research and Development of an Investigational Oncology Product
06/08/2020
Voluntary Announcement – Nadroparin Calcium for Injection obtained Drug Registration Approval
16/07/2020
Voluntary Announcement – Update on the Introduction and Research and Development of an Investigational Oncology Product
13/07/2020
Voluntary Announcement – Update on an Investigational Inhaled Antipsychotic Product
09/07/2020
Voluntary Announcement – Possible Spin-off and Separate Listing of China Ophthalmology Focus Limited
02/07/2020
Voluntary Announcement – Update on the In-Licensing and Research and Development of Ophthalmology Products
26/06/2020
Voluntary Announcement – Unidrox Prulifloxacin Tablet Obtained Imported Drug License from China’s National Medical Products Administration
22/06/2020
Voluntary Announcement – Update on an Investigational Dermatology Product
12/05/2020
Voluntary Announcement – Update on an Investigational Inhaled Antipsychotic Product
08/05/2020
Voluntary Announcement – Update on an Investigational Oncology Product
08/05/2020
Voluntary Announcement – Update on the In-Licensing and Research and Development of Ophthalmology Products
14/04/2020
Voluntary Announcement – Appointment of Chief Strategy Officer specialising in Ophthalmology
14/04/2020
Voluntary Announcement – Update on an Investigational Dermatology Product
19/03/2020
Voluntary Announcement – Treprostinil Injection Obtained Approval for Drug Registration
16/03/2020
Voluntary Announcement – Update on an Inhalation Gas Product
10/03/2020
Voluntary Announcement – Aliskiren Combined with Nifedipine Obtained Approval from West China Hospital Biomedical Ethics Committee of Sichuan University to Conduct Clinical Trial on the Treatment of Hypertension Patient with Confirmed COVID-19 Pneumonia
10/03/2020
Voluntary Announcement – Business Update of an Associated Company of the Group
06/02/2020
Voluntary Announcement – Update of Business Development with Italfarmaco
03/02/2020
Voluntary Announcement – Update on Business Development
13/01/2020
Voluntary Announcement – Update on an Investigational Ophthalmology Product
22/11/2019
Voluntary Announcement – Update on the Introduction and Research and Development of an Investigational Dermatology Product
30/10/2019
Voluntary Announcement – Update on the Introduction and Research and Development of an Investigational Ophthalmology Product
02/09/2019
Voluntary Announcement – Share Repurchase Program under the Repurchase Mandate
20/12/2018
VOLUNTARY ANNOUNCEMENT – COLLABORATION AND LICENSE AGREEMENT WITH AURANSA
29/11/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON THE RESEARCH AND DEVELOPMENT OF A NOVEL PERCUTANEOUS OPTICAL FIBRE CONTINUOUS GLUCOSE SENSOR
10/10/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON THE INTRODUCTION AND RESEARCH AND DEVELOPMENT OF AN INVESTIGATIONAL ONCOLOGY PRODUCT
10/09/2018
VOLUNTARY ANNOUNCEMENT – INCLUSION IN THE HONG KONG STOCK CONNECT LIST UNDER THE SHENZHEN-HONG KONG STOCK CONNECT
07/09/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON THE INTRODUCTION AND RESEARCH AND DEVELOPMENT OF AN INVESTIGATIONAL ONCOLOGY PRODUCT
29/08/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON THE INTRODUCTION AND RESEARCH AND DEVELOPMENT OF AN INVESTIGATIONAL ANTICOAGULANT
16/08/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON A GRANISETRON TRANSDERMAL PATCH PRODUCT
09/07/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON AN INVESTIGATIONAL ANAESTHESIA PRODUCT
26/06/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON AN INVESTIGATIONAL OPHTHALMOLOGY PRODUCT
14/06/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON AN INVESTIGATIONAL ONCOLOGY PRODUCT
23/05/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON THE INTRODUCTION AND RESEARCH AND DEVELOPMENT OF AN INVESTIGATIONAL ONCOLOGY
14/02/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON THE LICENSING IN AND RESEARCH AND DEVELOPMENT OF AN INVESTIGATIONAL ANTICOAGULANT
29/01/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON THE LICENSED-IN AND RESEARCH AND DEVELOPMENT OF AN ONCOLOGY PRODUCT
29/01/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON THE LICENSED-IN AND RESEARCH AND DEVELOPMENT OF AN ANTIHYPERTENSIVE DRUG
26/01/2018
VOLUNTARY ANNOUNCEMENT – UPDATE ON THE LICENSED-IN AND RESEARCH AND DEVELOPMENT OF A NEEDLE-FREE PERCUTANEOUS INJECTION DRUG DELIVERY SYSTEM PRODUCT
